Interleukin News and Research

RSS

OncoSec establishes UW as second enrolling site for OMS-I100 Phase II metastatic melanoma trial

OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that it has established the University of Washington (UW) as the second enrolling site for its Phase II metastatic melanoma clinical trial (OMS-I100).

25 Sep 2012

Interleukin-6 could affect hunger and satiety

Researchers at the Sahlgrenska Academy, University of Gothenburg, Sweden, have identified a molecule in the immune system that could affect hunger and satiety. The researchers hope that new treatments for obesity will benefit from this finding.

24 Sep 2012

GSK3 inhibition protects against gum disease

Treatment with the cell-permeable glycogen synthase kinase -3β-specific enzyme inhibitor SB216763 successfully suppresses alveolar bone loss in mice infected with the main periodontal pathogen, Porphyromonas gingivalis, report researchers.

20 Sep 2012

Nonsurgical treatment achieves periodontitis improvements regardless of smoking

Both smokers and nonsmokers with the chronic inflammatory disease periodontitis have significantly improved clinical markers, including probing depth and plaque index, after nonsurgical periodontal therapy, show study results.

11 Sep 2012

Interleukin-18 plays a key role in inflammation

The naturally occurring cytokine interleukin-18, or IL-18, plays a key role in inflammation and has been implicated in serious inflammatory diseases for which the prognosis is poor and there are currently limited treatment options.

7 Sep 2012

Newly discovered neuronal pathway plays key role in controlling bone density during adolescence

Researchers at the Hebrew University of Jerusalem have discovered that a neuronal pathway -- part of the autonomic nervous system -- reaches the bones and participates in the control of bone development.

5 Sep 2012

Alder’s initiation of ALD518/BMS-945429 Phase 2 trial triggers $3.5M milestone payment

Alder Biopharmaceuticals Inc. today announced it has received a $3.5 million milestone payment from Bristol-Myers Squibb for the initiation of a Phase 2 clinical trial of ALD518/BMS-945429, an investigational antibody therapeutic that blocks interleukin-6 (IL-6), in Crohn's disease.

28 Aug 2012

Salivary IL-6 could predict recurrence after surgery in mouth cancer patients

Salivary levels of the proinflammatory cytokine interleukin-6 could be a useful predictor for locoregional recurrence in oral squamous cell carcinoma patients who are treated surgically, report researchers.

23 Aug 2012

Cardiac benefit of exercise proves better late than never

Even individuals who start exercising for 2.5 hours per week in their late 40s and 50s have better cardiovascular health than those who do not adhere to an exercise regimen, say researchers.

15 Aug 2012

Ingredient for butter flavor in microwave popcorn is a respiratory hazard

The ingredient 2,3-pentanedione (PD), used to impart the flavor and aroma of butter in microwave popcorn, is a respiratory hazard that can also alter gene expression in the brain of rats. Manufacturers started using PD when another butter flavoring, diacetyl, was found to cause bronchiolitis obliterans, a life-threatening and nonreversible lung disease in workers who inhaled the substance.

13 Aug 2012

Researchers uncover new key player in amplifying stress in early stages of diabetes

At its most fundamental level, diabetes is a disease characterized by stress—microscopic stress that causes inflammation and the loss of insulin production in the pancreas, and system-wide stress due to the loss of that blood-sugar-regulating hormone.

9 Aug 2012

Blood levels of IL-6 protein may also serve as red flag for relapse in schizophrenia patients

Blood levels of a protein that helps regulate inflammation may also serve as a red flag for relapse in some schizophrenia patients, researchers said.

7 Aug 2012

Possible molecular link between circadian rhythm disturbances and increased inflammatory response

Scientists have known for some time that throwing off the body's circadian rhythm can negatively affect body chemistry. In fact, workers whose sleep-wake cycles are disrupted by night shifts are more susceptible to chronic inflammatory diseases such as diabetes, obesity and cancer.

2 Aug 2012

Researchers develop bioactive coating that actively suppresses brain's immune response

Brain-computer interfaces are at the cutting edge for treatment of neurological and psychological disorder, including Parkinson's, epilepsy, and depression. Among the most promising advance is deep brain stimulation (DBS) - a method in which a silicon chip implanted under the skin ejects high frequency currents that are transferred to the brain through implanted electrodes that transmit and receive the signals.

1 Aug 2012

Gluconeogenesis severely compromised in HCC by IL6-Stat3-mediated activation of miR-23a

As liver cancer develops, tumor cells lose the ability to produce and release glucose into the bloodstream, a key function of healthy liver cells for maintaining needed blood-sugar levels.

31 Jul 2012

OX40 molecule responsible for airway inflammation in the lungs

A research team led by Xian Chang Li, MD, PhD, Brigham and Women's Hospital (BWH) Transplantation Research Center, has shed light on how a population of lymphocytes, called CD4+ T cells, mature into various subsets of adult T helper cells.

30 Jul 2012

Long-term use of reverse geometry lenses may induce inflammatory response

Continuous long-term overnight use of reverse geometry lenses results in a significantly increased presence of inflammatory mediators compared with wearing 30-night silicone-hydrogel contact lenses or wearing no lenses, show study results.

27 Jul 2012

Anakinra can dramatically limit amount of brain damage in stroke patients

Scientists led by the President of The University of Manchester have demonstrated a drug which can dramatically limit the amount of brain damage in stroke patients.

From The University of Manchester 27 Jul 2012

High-dose IL-2 still the most effective treatment for patients with stage IV metastatic melanoma

Administering high-doses of interleukin-2 (IL-2) has been the preferred treatment for patients with stage IV metastatic melanoma. An article published in the current issue of Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc., explores whether or not this regimen is still the most effective.

26 Jul 2012

Researchers discover reason why breast cancer cells become drug resistant

Breast cancer treatments such as Herceptin that target a marker called HER2 have dramatically improved outcomes for women with this type of cancer. But nearly half of these cancers are resistant to Herceptin from the start and almost all of them will eventually become resistant.

21 Jul 2012